Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Who's Developing What in Drug Delivery 2009
Management Report
Published: November 2009
Pages: 830
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Medical Devices
s report will enable you to understand the structure, performance, R&D and products of 130 leading drug delivery companies.competitive evaluation covering over 150 companies active in the area.
The indispensible 2-volume guide to the companies that are shaping this critical area.
The importance of drug delivery technology grows ever more acute and commercial and industry interest is continuing to build. The benefits to patients can be seen in improved medical outcomes, while the pharmaceutical industry is able to extend patent protection through novel delivery regimes, and bring new therapies to the market that would, previously, have been impossible to administer.
Consequently, the drug delivery sector has evolved from being simply a part of the pharmaceutical production process to a driving force for innovation and profits. As a result, developers of drug delivery products and technology have benefited from significant attention from customers and investors alike, and merger and acquisition activity is notable.
The credit crunch has taken its toll, but investors are returning
Many drug delivery development companies have been hit hard by the recession. With investor capital in short supply to fund technology developments, many smaller companies have failed. Positively, there have been signs on the horizon that investors are returning to the sector, but investment is more focused on innovative technologies that have a good chance of achieving commercial returns.
Drug Delivery:
the critical ingredient in any drug development or life-cycle extension programme
While pharmaceutical sales have risen steadily over the last five years, generating over US$720 billion in 2008, analysts are forecasting sales growth will slow over the next five years due to an unprecedented level of patent expiration compounded by the downturn in the global economy. At the same time, the global drug delivery market has tripled in value from an estimated US$26 billion in 2000.
This market has been driven by a number of factors including:
Patent expiration of leading brands forcing the pharmaceutical industry to evaluate ways to maximize product life-cycles through new formulations, combinations and repositioning;
Advances in new delivery technology (microencapsulation and nanotechnology); and
The development and cost-effective manufacture of new delivery materials (dendrimers, lipid formulations and biodegradable polymers).
Within the drug-delivery market, there are a number of areas of advanced drug delivery which have attracted the attention of the pharmaceutical industry and the investment community. The dramatic growth of the sector is reflected in the evolution of an array of delivery vehicles and hybrid platforms that are increasingly being used to deliver approved and novel therapeutic agents.
Understand the competitive landscape...
For researchers, drug developers, commercial management and investors the need to understand the strengths, weakness, products and position of drug-delivery companies that are leading the way is critical. This new 748-page, 2-volume report - issued by the publishers of Drug Delivery Insight and a range of related reports - has become the essential resource for assessing drug delivery companies worldwide.
The importance of drug delivery technology grows ever more acute and commercial and industry interest is continuing to build. The benefits to patients can be seen in improved medical outcomes, while the pharmaceutical industry is able to extend patent protection through novel delivery regimes, and bring new therapies to the market that would, previously, have been impossible to administer.
Consequently, the drug delivery sector has evolved from being simply a part of the pharmaceutical production process to a driving force for innovation and profits. As a result, developers of drug delivery products and technology have benefited from significant attention from customers and investors alike, and merger and acquisition activity is notable.
The credit crunch has taken its toll, but investors are returning
Many drug delivery development companies have been hit hard by the recession. With investor capital in short supply to fund technology developments, many smaller companies have failed. Positively, there have been signs on the horizon that investors are returning to the sector, but investment is more focused on innovative technologies that have a good chance of achieving commercial returns.
Drug Delivery:
the critical ingredient in any drug development or life-cycle extension programme
While pharmaceutical sales have risen steadily over the last five years, generating over US$720 billion in 2008, analysts are forecasting sales growth will slow over the next five years due to an unprecedented level of patent expiration compounded by the downturn in the global economy. At the same time, the global drug delivery market has tripled in value from an estimated US$26 billion in 2000.
This market has been driven by a number of factors including:
Patent expiration of leading brands forcing the pharmaceutical industry to evaluate ways to maximize product life-cycles through new formulations, combinations and repositioning;
Advances in new delivery technology (microencapsulation and nanotechnology); and
The development and cost-effective manufacture of new delivery materials (dendrimers, lipid formulations and biodegradable polymers).
Within the drug-delivery market, there are a number of areas of advanced drug delivery which have attracted the attention of the pharmaceutical industry and the investment community. The dramatic growth of the sector is reflected in the evolution of an array of delivery vehicles and hybrid platforms that are increasingly being used to deliver approved and novel therapeutic agents.
Understand the competitive landscape...
For researchers, drug developers, commercial management and investors the need to understand the strengths, weakness, products and position of drug-delivery companies that are leading the way is critical. This new 748-page, 2-volume report - issued by the publishers of Drug Delivery Insight and a range of related reports - has become the essential resource for assessing drug delivery companies worldwide.